Latest News

Delpacibart etedesiran did not demonstrate statistically significant improvement in myotonic dystrophy type 1 in the phase 3 HARBOR study, despite reported signals of clinical activity across secondary and exploratory measures.

An indirect comparison found zorevunersen-treated patients with Dravet syndrome showed greater gains in adaptive functioning and behavior than natural history patients.

A randomized clinical trial found that intravenous tirofiban plus aspirin did not significantly reduce early neurological deterioration or new stroke compared with aspirin alone i patients with branch atheromatous disease–related stroke.

A recent study of Brazilian adolescents showed a high prevalence of excessive daytime sleepiness, with severe depressive symptoms and smartphone addiction emerging as the strongest independent risk factors.

Here's some of what is coming soon to NeurologyLive® this week.

Newly published KINECT-PRO data showed that valbenazine boosted quality of life and function while reducing movement severity, with remission for many patients with tardive dyskinesia by 24 weeks.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 4, 2026.

Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease.

Findings from a new study showed that over 90% of counties in the United States lacked a UCNS-certified headache specialist, with access lowest in socioeconomically disadvantaged and rural areas.

Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.

FDA approved Zanvastro (zilganersen), the first therapy to directly target the GFAP protein buildup that drives Alexander disease, based on a phase 3 trial showing improved walking speed and motor function versus untreated controls.

A recent study suggests that cumulative genetic variation associated with lymphocyte counts may help identify patients living with multiple sclerosis at increased risk of dimethyl fumarate-associated lymphopenia.

Newly published longitudinal fMRI data revealed that presymptom Huntington gene carriers had striatal network shifts up to 20 years early, potentially sharpening targets for studies in the future.